PRESTO P2X Receptors as Therapeutic Opportunity an EU COST Action. Understanding the role of P2XRs in inflammatory, infectious, neurologic and oncologic diseases and fostering the development of P2XR-targeting therapies. Read more

Working groups

WG2 P2XR in neurodegenerative diseases and depression

WG3 Role of P2XRs in cancer and tissue regeneration

Over 135 members

from 28 Countries

More that 50% of woman

35% of Young investigators

Latest news
1 June 2023

WEBINAR

Webinar 2023 with talks from Luísa V. Lopes, Portugal; Jean Sévigny, Canada & Elena Adinolfi, Italy. Click here for more...
22 February 2023

#PRESTO cost meeting has made the local news!

The first #PRESTO cost meeting has made the local news! read more here: https://www.ferraratoday.it/cronaca/presto-meeting-progetto-europeo-dedicato-studio-nuovi-farmaci-contro-malattie-degenerative.html #prestocost2023 #P2X
22 February 2023

1st Management Committee Meeting of the COST Action

CA21130 – P2X receptors as a therapeutic opportunity (PRESTO) Agenda and Materials The agenda is in Annex 1. The meeting...
31 January 2023

STSMs

Short term scientific missions(STSMs) allow scientists to conduct brief research and study visits to a research institution or laboratory in...
Latest Instagram posts
Funded by
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.